BLU.TO (Mkap $22 M) Big Rare Disease Drug in Phase3 = 500%++ Potential (Seite 10)
eröffnet am 29.01.14 15:27:44 von
neuester Beitrag 18.04.23 18:43:43 von
neuester Beitrag 18.04.23 18:43:43 von
Beiträge: 381
ID: 1.190.903
ID: 1.190.903
Aufrufe heute: 0
Gesamt: 86.322
Gesamt: 86.322
Aktive User: 0
ISIN: CA07987C2040 · WKN: A2PQKK · Symbol: BLU
14,740
USD
0,00 %
0,000 USD
Letzter Kurs 29.06.23 Nasdaq
Neuigkeiten
16.06.23 · Business Wire (engl.)  |
16.05.23 · Business Wire (engl.) |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 8,8800 | +57,45 | |
| 17,440 | +44,61 | |
| 1,8400 | +26,03 | |
| 4,9500 | +25,32 | |
| 4,0000 | +25,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,965 | -18,48 | |
| 0,7845 | -19,36 | |
| 3,3200 | -22,61 | |
| 0,6785 | -26,19 | |
| 3,3100 | -77,44 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 51.453.603 von olli60 am 09.01.16 18:09:45na dann wird VSVI ja seinen Hedgie-Freunden mal ne Info zukommen lassen. Und wir haben das Tal der Tränen endgültig hinter uns gelassen.
Beste Grüße
Beste Grüße
Antwort auf Beitrag Nr.: 51.441.564 von Karltill21 am 08.01.16 09:07:04Übrigens wurde durch Victoria Square Ventures Inc. (VSVI), welche 7,286,828 neue Aktien für die
Ablösung ihrer 10,9 Mio.$ Wandelanleihe erhalten, rein rechnerisch 1,495 CAD je Aktie gezahlt.
VSVI wird schon wissen warum sie mehr als den derzeitigen Kurs zahlen, VSVI hält jetzt 32,5% aller
Bellus-Aktien.
Ablösung ihrer 10,9 Mio.$ Wandelanleihe erhalten, rein rechnerisch 1,495 CAD je Aktie gezahlt.
VSVI wird schon wissen warum sie mehr als den derzeitigen Kurs zahlen, VSVI hält jetzt 32,5% aller
Bellus-Aktien.
Antwort auf Beitrag Nr.: 51.441.564 von Karltill21 am 08.01.16 09:07:04Präsentation hat sich meiner Meinung kaum verändert. Was andere für was mal bekommen ist vielleicht schön, hat aber nix mit der Firma und Produkt selbst zu tun. Deswegen für mich uninteressant.
Ich finde den möglichen sales peak sehr interessant, wobei hier noch mit dem Partner 50/50% geteilt wird.
Bald müsste eigentlich eine Meldung über den Studienabschluss kommen, schließlich wurde berichtet, dass 95% der Studie durch sind. Dann warten bis mitte 2016.
Ich finde den möglichen sales peak sehr interessant, wobei hier noch mit dem Partner 50/50% geteilt wird.
Bald müsste eigentlich eine Meldung über den Studienabschluss kommen, schließlich wurde berichtet, dass 95% der Studie durch sind. Dann warten bis mitte 2016.
Antwort auf Beitrag Nr.: 51.405.618 von olli60 am 04.01.16 13:08:20
Allen Investierten ein erfolgreiches Jahr 2016...natürlich auch in Hinsicht auf die Bellusentwicklung.
http://s1.q4cdn.com/543273785/files/doc_presentations/2016/B…
Ich glaube, die Dilution war in einem Filling angekündigt. Hat dem Kurs keineswegs geschadet. VSVI weiß, was sie tun. Die wissen immer mehr als Retail.
Beste Grüße
Interessant...und nochmals interessant
da hat sich Bellus in diesen schwierigen Zeiten doch sehr gut gehalten...und jetzt kommt R. Bellini mit seiner Winterpräsentation. Neben vielen anderen interessanten Dingen, finde ich insbesondere S. 16 prima.Allen Investierten ein erfolgreiches Jahr 2016...natürlich auch in Hinsicht auf die Bellusentwicklung.
http://s1.q4cdn.com/543273785/files/doc_presentations/2016/B…
Ich glaube, die Dilution war in einem Filling angekündigt. Hat dem Kurs keineswegs geschadet. VSVI weiß, was sie tun. Die wissen immer mehr als Retail.
Beste Grüße
Hat jemand eine Meinung hierzu:
Bellus Health announces scheduled settlement of convertible notes
CNW Group BELLUS Health Inc.
January 1, 2016 10:00 AM
- Issuance of 7,286,828 common shares in settlement of convertible notes -
LAVAL, QC , Jan. 1, 2016 /CNW/ - BELLUS Health Inc. (BLU.TO) (BELLUS Health or the Company), a drug development company focused on rare diseases, today announced the scheduled issuance of 7,286,828 common shares from treasury to Victoria Square Ventures Inc. (VSVI) in settlement of convertible notes. The settlement further simplifies the Company's capital structure.
The convertible notes' notional amount was approximately $10.9 million and terms of the conversion were determined as part of BELLUS Health's capital reorganization in 2012. Subsequent to the settlement, VSVI now holds 32.5% of the Company's issued and outstanding common shares and 27.0% on a fully diluted basis.
"The settlement of these convertible notes is the penultimate step to the completion of our capital structure's simplification that started in 2012", said Roberto Bellini , President and Chief Executive Officer of BELLUS Health. "We expect that the conversion of the second and final equity-like instrument, being the Pharmascience Exchange Right, will occur by the fourth quarter of 2016."
The Company now has approximately 54.7 million common shares outstanding and 65.7 million common shares on a fully diluted basis. Dilution items include approximately 4.7 million common shares issuable under the stock option plan and 6.4 million common shares issuable upon the exercise by Pharmascience of its right to exchange its 10.4% interest in the limited partnership carrying out BELLUS Health's activities (the Exchange Right). On or after September 30, 2016 , BELLUS Health has the right, which the Company expects to exercise, to force the conversion of the Pharmascience Exchange Right.
For further information, please see a recent blog post by the Company's Vice President, Finance, François Desjardins on the BELLUS Health website at www.bellushealth.com.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a drug development company focused on rare diseases. Its pipeline of rare disease projects includes KIACTA™ in Phase III for AA amyloidosis, KIACTA™ for sarcoidosis, clinical stage Shigamab™ for sHUS and a research-stage project for AL amyloidosis. The lead program KIACTA™ is currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTA™.
Forward-Looking Statements
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute "forward-looking statements" within the meaning of Canadian securities legislation and regulations. Such statements, based as they are on the current expectations of management, inherently involve numerous important risks, uncertainties and assumptions, known and unknown, many of which are beyond BELLUS Health Inc.'s control. Such risks factors include but are not limited to: the ability to obtain financing, the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which the BELLUS Health Inc. does business, stock market volatility, fluctuations in costs, changes to the competitive environment due to consolidation, achievement of forecasted burn rate, potential payments/outcomes in relation to indemnity agreements and contingent value rights, achievement of forecasted pre-clinical and clinical trial milestones, dependence on Auven Therapeutics for the completion of the KIACTA™Phase III Confirmatory Study and that actual results may vary once the final and quality-controlled verification of data and analyses has been completed. In addition, the length of the KIACTATM Phase III Confirmatory Study and the sharing of proceeds between Auven Therapeutics and BELLUS Health Inc. from potential future revenue of KIACTA™ is dependent upon a number of factors, including the quantum of proceeds. Consequently, actual future results and events may differ materially from the anticipated results and events expressed in the forward-looking statements. The Company believes that expectations represented by forward-looking statements are reasonable, yet there can be no assurance that such expectations will prove to be correct. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These forward-looking statements speak only as of the date made, and BELLUS Health Inc. is under no obligation and disavows any intention to update publicly or revise such statements as a result of any new information, future event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see BELLUS Health Inc.'s public filings with the Canadian securities regulatory authorities, including the Annual Information Form, for further risk factors that might affect BELLUS Health Inc. and its business.
SOURCE BELLUS Health Inc.
Quelle: http://finance.yahoo.com/news/bellus-health-announces-schedu…
Bellus Health announces scheduled settlement of convertible notes
CNW Group BELLUS Health Inc.
January 1, 2016 10:00 AM
- Issuance of 7,286,828 common shares in settlement of convertible notes -
LAVAL, QC , Jan. 1, 2016 /CNW/ - BELLUS Health Inc. (BLU.TO) (BELLUS Health or the Company), a drug development company focused on rare diseases, today announced the scheduled issuance of 7,286,828 common shares from treasury to Victoria Square Ventures Inc. (VSVI) in settlement of convertible notes. The settlement further simplifies the Company's capital structure.
The convertible notes' notional amount was approximately $10.9 million and terms of the conversion were determined as part of BELLUS Health's capital reorganization in 2012. Subsequent to the settlement, VSVI now holds 32.5% of the Company's issued and outstanding common shares and 27.0% on a fully diluted basis.
"The settlement of these convertible notes is the penultimate step to the completion of our capital structure's simplification that started in 2012", said Roberto Bellini , President and Chief Executive Officer of BELLUS Health. "We expect that the conversion of the second and final equity-like instrument, being the Pharmascience Exchange Right, will occur by the fourth quarter of 2016."
The Company now has approximately 54.7 million common shares outstanding and 65.7 million common shares on a fully diluted basis. Dilution items include approximately 4.7 million common shares issuable under the stock option plan and 6.4 million common shares issuable upon the exercise by Pharmascience of its right to exchange its 10.4% interest in the limited partnership carrying out BELLUS Health's activities (the Exchange Right). On or after September 30, 2016 , BELLUS Health has the right, which the Company expects to exercise, to force the conversion of the Pharmascience Exchange Right.
For further information, please see a recent blog post by the Company's Vice President, Finance, François Desjardins on the BELLUS Health website at www.bellushealth.com.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a drug development company focused on rare diseases. Its pipeline of rare disease projects includes KIACTA™ in Phase III for AA amyloidosis, KIACTA™ for sarcoidosis, clinical stage Shigamab™ for sHUS and a research-stage project for AL amyloidosis. The lead program KIACTA™ is currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTA™.
Forward-Looking Statements
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute "forward-looking statements" within the meaning of Canadian securities legislation and regulations. Such statements, based as they are on the current expectations of management, inherently involve numerous important risks, uncertainties and assumptions, known and unknown, many of which are beyond BELLUS Health Inc.'s control. Such risks factors include but are not limited to: the ability to obtain financing, the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which the BELLUS Health Inc. does business, stock market volatility, fluctuations in costs, changes to the competitive environment due to consolidation, achievement of forecasted burn rate, potential payments/outcomes in relation to indemnity agreements and contingent value rights, achievement of forecasted pre-clinical and clinical trial milestones, dependence on Auven Therapeutics for the completion of the KIACTA™Phase III Confirmatory Study and that actual results may vary once the final and quality-controlled verification of data and analyses has been completed. In addition, the length of the KIACTATM Phase III Confirmatory Study and the sharing of proceeds between Auven Therapeutics and BELLUS Health Inc. from potential future revenue of KIACTA™ is dependent upon a number of factors, including the quantum of proceeds. Consequently, actual future results and events may differ materially from the anticipated results and events expressed in the forward-looking statements. The Company believes that expectations represented by forward-looking statements are reasonable, yet there can be no assurance that such expectations will prove to be correct. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These forward-looking statements speak only as of the date made, and BELLUS Health Inc. is under no obligation and disavows any intention to update publicly or revise such statements as a result of any new information, future event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see BELLUS Health Inc.'s public filings with the Canadian securities regulatory authorities, including the Annual Information Form, for further risk factors that might affect BELLUS Health Inc. and its business.
SOURCE BELLUS Health Inc.
Quelle: http://finance.yahoo.com/news/bellus-health-announces-schedu…
Trading Spotlight
Kein Spaß ist folgendes : rund 445 Mill. Deficit, alle Achtung !!
Shareholders' equity:
Share capital (note 9 (a)) 418,592 418,592
Other equity (notes 9 (b) and 10 (c)) 34,004 33,770
Accumulated other comprehensive income 403 230
Deficit (444,857) (444,194)
Shareholders' equity:
Share capital (note 9 (a)) 418,592 418,592
Other equity (notes 9 (b) and 10 (c)) 34,004 33,770
Accumulated other comprehensive income 403 230
Deficit (444,857) (444,194)
Antwort auf Beitrag Nr.: 51.353.391 von olli60 am 22.12.15 15:18:56Ja, war über Weihnachten kurz im Urlaub und wünsche Dir Olli als einer der wenigen offiziellen Investierten und allen anderen Investierten alles Gute zu den Feiertagen und immer ein gutes Händchen bei den zukünftigen Investitionen.
Beste Grüße
Beste Grüße
Da hat heute einer um 12.50Uhr, in Stuttgart und Frankfurt je 7 Aktien gekauft, was für ein Spaßvogel!
Oder aber, er hat sein gesamtes Weihnachtsgeld gut angelegt.
Wünsche auf diesem Weg, allen investierten ein frohes und erholsames Weihnachtsfest und ein
erfolgreiches neues Jahr.
Oder aber, er hat sein gesamtes Weihnachtsgeld gut angelegt.
Wünsche auf diesem Weg, allen investierten ein frohes und erholsames Weihnachtsfest und ein
erfolgreiches neues Jahr.
Antwort auf Beitrag Nr.: 51.295.431 von kalpchen am 13.12.15 12:43:47Sehe ich ähnlich wie Kalpchen. Auf der anderen Seite lag Olli mit der Charttechnik letztes Mal auch ziemlich richtig.
Hier aber der vermeintliche Grund des Anstiegs:
http://business.financialpost.com/news/how-this-montreal-com…
Auch wenn die Zeithorizonte etwas größer sind...Bellus ist eine Perle.
Beste Grüße
Hier aber der vermeintliche Grund des Anstiegs:
http://business.financialpost.com/news/how-this-montreal-com…
Auch wenn die Zeithorizonte etwas größer sind...Bellus ist eine Perle.
Beste Grüße
Durchsuchen
